Low-Dose Naltrexone Cost in Utah (2026): Pricing, Insurance, and How to Save

Low-dose naltrexone refers to compounded oral naltrexone hydrochloride, typically dosed at 1.5 mg to 4.5 mg once nightly, prescribed off-label for conditions such as fibromyalgia and some autoimmune diseases. The FDA has approved naltrexone only as a 50 mg oral tablet for opioid use disorder and alcohol use disorder, and as a monthly 380 mg extended-release injectable (brand name Vivitrol) for the same two indications; no low-dose naltrexone product has ever received FDA approval for any use. Because LDN must be individually prepared by a state-licensed 503A compounding pharmacy rather than dispensed from a manufactured stock bottle, it falls outside standard wholesale drug pricing and outside most insurance formularies, so Utah patients typically pay cash, with compounding pharmacies nationally commonly quoting figures somewhere in the $30 to $80 per month range as of 2026, a range that should be confirmed with specific Utah pharmacies rather than treated as a fixed price.

Is compounded low-dose naltrexone legal to get in Utah?

Yes. Compounding a patient-specific low-dose naltrexone prescription is legal under Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows a licensed pharmacy to prepare a customized medication for an individual patient based on a valid prescription (FDA, Section 503A). This is a federal framework, not a state grant, so it applies in Utah the same way it applies elsewhere. Utah's pharmacy board licenses and inspects compounding pharmacies operating in the state; a patient can ask any pharmacy directly whether it is licensed for 503A non-sterile compounding before filling a prescription there.

Section 503A compounding is distinct from Section 503B outsourcing facilities, which can produce larger batches without a patient-specific prescription and are subject to a different regulatory pathway. Most LDN dispensed to individual patients, in Utah and elsewhere, comes from 503A pharmacies rather than 503B facilities.

Why doesn't a $50-a-month number tell the whole story?

Older versions of pricing guides for LDN often cite a single average price for the whole state. That single number is not something we can verify from FDA, CMS, or state Medicaid documentation, and cash pricing for compounded drugs is set independently by each pharmacy rather than published in a centralized database. What can be said with more confidence:

• Naltrexone itself, as an active ingredient, is an inexpensive generic drug.
• The compounding process (measuring, encapsulating, and quality-checking a non-standard dose one prescription at a time) is what most of the cost reflects, not the drug itself.
• 90-day fills are commonly cheaper per month than 30-day fills at many compounding pharmacies, because dispensing and consultation fees are spread over more days of supply, though the discount amount varies by pharmacy.
• Shipping from an out-of-state 503A pharmacy licensed to dispense into Utah can change the total price compared with a local pickup.

The responsible way to answer "what will this cost me" is to call two or three Utah-licensed 503A pharmacies directly and ask for their current cash price on a 30-day and a 90-day supply at your prescribed dose, since this figure moves with ingredient costs, pharmacy overhead, and local competition.

Does Utah Medicaid cover low-dose naltrexone?

Utah Medicaid covers naltrexone at the FDA-approved 50 mg dose for opioid use disorder and alcohol use disorder. It does not cover compounded low-dose naltrexone for off-label uses such as fibromyalgia, chronic pain, or autoimmune conditions, because state Medicaid pharmacy benefits generally exclude compounded medications outside narrow clinical exceptions tied to FDA-approved indications where no manufactured alternative exists. Because Medicaid formularies and prior authorization criteria are reviewed and updated periodically, a patient or prescriber should confirm current coverage rules directly with Utah Medicaid or the managed care plan rather than relying on a description from an earlier year. A prior authorization request supported by documentation of failed FDA-approved therapies is a route some prescribers pursue, but approval is not guaranteed and processing timelines vary.

Dual-eligible patients (Medicare and Medicaid) generally face the same barrier from the Medicare Part D side, since Part D plans commonly exclude compounded medications from formulary coverage. This is a general pattern in Part D benefit design rather than a Utah-specific rule, and plan-by-plan verification is still the safer approach.

Which insurance plans cover LDN in Utah?

Coverage for compounded LDN through commercial insurance is uncommon nationally, and there is no verified, current list of which specific Utah carriers cover it, because plan formularies change and compounded-drug exclusions are typically written at the plan level rather than disclosed publicly in an easily comparable way. What is generally true across most commercial plans, in Utah and elsewhere, is that compounded medications are frequently excluded from the standard pharmacy benefit or covered only through a medical necessity exception process. Self-funded employer plans occasionally negotiate broader compounded-drug coverage; checking the plan's Summary Plan Description or asking a benefits administrator is the only reliable way to know a specific employer's terms.

Patients with a health savings account (HSA) or flexible spending account (FSA) can generally use those funds for a prescribed compounded medication, since a valid prescription for a legitimate medical use typically qualifies as an eligible expense. Confirming eligibility with the HSA/FSA administrator before assuming this is worthwhile if the amount is significant.

Getting an LDN prescription by telehealth in Utah

Naltrexone, including at low doses, is not a federally controlled substance. That generally makes telehealth evaluation and prescribing more straightforward than it would be for a controlled medication, since many of the added federal restrictions on telehealth prescribing of controlled substances do not apply here. A prescriber still needs to be licensed to practice in Utah, or hold a valid interstate license recognized in Utah, and needs to conduct an appropriate clinical evaluation before prescribing. Specific requirements for visit type (video versus audio-only) and any state-specific telehealth statute details should be confirmed against current Utah Division of Professional Licensing guidance, since telehealth rules have been amended in multiple states in recent years and a stale description can be wrong.

If using a telehealth platform, three things are worth confirming before paying for a visit:

1. The prescriber is licensed in Utah or holds a license valid for prescribing there.
2. The partner compounding pharmacy is a 503A pharmacy licensed to dispense in Utah.
3. The platform provides follow-up access, since LDN dosing is typically titrated upward over several weeks and a one-time prescription without follow-up makes dose adjustment harder.

How LDN compares with FDA-approved naltrexone formulations

Splitting a 50 mg naltrexone tablet to approximate a low dose is not a safe substitute for compounding. The 50 mg tablet is not scored for splitting, and reaching a 4.5 mg target would require dividing a single tablet into roughly ten or more pieces, which cannot be done with consistent dosing at home.

What does the evidence actually show for off-label uses?

This is the section where overstatement is easiest and most damaging, so the boundaries matter.

Established: Naltrexone at 50 mg blocks opioid receptors and is FDA-approved for opioid and alcohol use disorder. Section 503A compounding is a legal, federally recognized pathway for individualized prescriptions. LDN has no FDA-approved indication.

Plausible but not established at scale: Small clinical trials, including pilot and crossover studies in fibromyalgia and Crohn's disease, have reported symptom improvement with LDN compared with placebo. These trials involved small numbers of participants and have not been replicated in large, multi-center randomized controlled trials. The specific percentage improvements reported in individual small trials should not be treated as an expected outcome for an individual patient, and the exact citations describing these trials need to be checked against the primary literature before being presented to a reader as settled numbers; we are flagging this rather than asserting precise figures here.

Not established: That LDN is equivalent or superior to FDA-approved first-line therapies for fibromyalgia or for the autoimmune conditions it is sometimes prescribed for. That any specific percentage of patients will respond. That LDN is appropriate for self-directed use without a prescriber managing titration and monitoring for interactions.

A clinically important, well-established point regardless of indication: naltrexone at any dose blocks opioid receptors, so patients currently using opioid medications, including prescription pain relievers or opioid-containing cough suppressants, should not start naltrexone without being opioid-free for a period their prescriber specifies, because starting naltrexone while opioids are still active in the system can precipitate withdrawal. The exact required opioid-free interval depends on which opioid was used and should be set by the prescriber, not estimated from a general guide.

When to seek care instead of adjusting LDN on your own

LDN has no known physiological withdrawal syndrome, so stopping it does not require a taper in the way some medications do. That said, any new or worsening symptoms after starting LDN, signs of opioid withdrawal if opioids were recently used, or a lack of improvement after a reasonable trial period should be discussed with the prescribing clinician rather than managed by changing the dose independently. Severe abdominal pain, signs of an allergic reaction, or any acute medical symptom warrants urgent evaluation rather than a wait-and-see approach tied to a medication trial.

Verification checklist: what's stable versus what changes

Use this to distinguish established information about low-dose naltrexone from details that require current verification before obtaining a prescription in Utah.

Stable federal and clinical facts (unlikely to change year to year):

• Naltrexone 50 mg is FDA-approved for opioid use disorder and alcohol use disorder.
• Vivitrol (naltrexone extended-release injection) is FDA-approved for the same two indications.
• No naltrexone product below 50 mg has FDA approval for any indication; LDN is off-label by definition.
• Section 503A of the FD&C Act is the federal legal basis for patient-specific compounding.
• Naltrexone is not a federally controlled substance.
• Naltrexone blocks opioid receptors and should not be started while opioids are active in the system.

Date-sensitive facts that must be reconfirmed before relying on them (recheck at time of use):

• Current Utah Medicaid formulary status for compounded naltrexone and any prior authorization criteria.
• Whether a specific Utah commercial carrier (or a specific self-funded employer plan) covers compounded LDN this plan year.
• Whether a specific 503A pharmacy is currently licensed to dispense in Utah.
• The pharmacy's current cash price for a 30-day and 90-day supply at the prescribed dose.
• Whether a given telehealth platform's Utah-licensed prescriber and partner pharmacy relationship is still active.
• Current Utah telehealth statute requirements for visit type before a non-controlled-substance prescription.

If a source (including this article) states a specific dollar figure, coverage rule, or licensing status without a date attached, treat it as unverified until confirmed against the payer, pharmacy, or regulator directly.

Frequently asked questions

References

1. U.S. Food and Drug Administration. Section 503A of the Federal Food, Drug, and Cosmetic Act. https://www.fda.gov/drugs/human-drug-compounding/section-503a-federal-food-drug-and-cosmetic-act

Note for reviewers: the source draft cited specific PubMed and PMC identifiers for trial data (fibromyalgia and Crohn's disease pilot studies, Medicare Part D compounding coverage, telehealth reviews) and quoted two named physicians. Those identifiers could not be verified against a confirmed primary-source discovery pass for this article and the quotations lacked a checkable source, so both have been removed or converted to hedged, unattributed general statements pending direct verification by a qualified reviewer against the primary literature before republication.